Concepedia

Daniel Gusenleitner

DG

Statistics

Publications

24

Citations

3.1K

H-Index

19

Active since

2011

Affiliations

Dana-Farber Cancer Institute(Current)

Massachusetts General Hospital

Harvard University

Brigham and Women's Hospital

Novartis (United States)

Daniel Gusenleitner is an author at Dana-Farber Cancer Institute specializing in oncology, medicine, and immune checkpoint inhibitors.

ORCID

Publications per year

2011–2024

24

Publications

24

Targetable genetic features of primary testicular and primary central nervous system lymphomas

Bjoern Chapuy, Margaretha G.M. Roemer, Chip Stewart et al. · Blood · 2015 · 599 citations · Full text

, , +16

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

Scott J. Rodig, Daniel Gusenleitner, Donald Jackson et al. · Science Translational Medicine · 2018 · 584 citations

, , +17

Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma

Christopher D. Carey, Daniel Gusenleitner, Mikel Lipschitz et al. · Blood · 2017 · 332 citations · Full text

, , +14

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients

Priyanka B. Subrahmanyam, Zhiwan Dong, Daniel Gusenleitner et al. · Journal for ImmunoTherapy of Cancer · 2018 · 193 citations · Full text

, , +17

Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade

Sachet A. Shukla, Pavan Bachireddy, Bastian Schilling et al. · Cell · 2018 · 172 citations · Full text

, , +12

1–5 of 24